# Post Hoc Analysis of Recombinant C1 Inhibitor Clinical Data Using Contemporary Endpoints for Hereditary Angioedema.

- **DOI:** [10.1007/s12325-026-03625-0](https://doi.org/10.1007/s12325-026-03625-0)
- **Rating:** Sound (3.4 out of 5)
- **Verdict:** A useful endpoint-harmonization reanalysis confirms rhC1-INH’s placebo-controlled efficacy, but mapped rather than directly measured contemporary outcomes constrain interpretation.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-09-18
- **Evaluation page:** https://www.nabu.science/paper/10.1007%2Fs12325-026-03625-0

## Key claims

1. Median TOSR was 0.75 h (95% CI, 0.55-1.50) with rhC1-INH and 8.00 h (95% CI, 3.00-8.05) with placebo (P < 0.001)
   - Support: Supported
   - Type: Primary finding
   - Basis: randomized pooled data show a large contrast, but TOSR depends on post hoc endpoint mapping
   - Location: Abstract; Results, Overall Pooled Analyses; Table 2
2. Median TTCR was 4.50 h (95% CI, 3.55-5.50) with rhC1-INH and 24.00 h (95% CI, 16.00->24.00) with placebo (P < 0.001)
   - Support: Supported
   - Type: Secondary
   - Basis: the large pooled contrast persists across threshold analyses, though TTCR is a mapped rather than measured endpoint
   - Location: Abstract; Results, Overall Pooled Analyses; Table 2
3. 75% of attacks were resolved within 6 h and 90% were resolved by 24 h
   - Support: Supported
   - Type: Secondary
   - Basis: landmark Kaplan–Meier estimates support the proportions, subject to the mapped PGI-S definition
   - Location: Key Summary Points; Results, Overall Pooled Analyses; Figure 3
4. rhC1-INH demonstrates significantly faster onset of symptom relief and resolution of HAE attacks compared with placebo, regardless of the efficacy outcome definition used
   - Support: Tentative
   - Type: Secondary
   - Basis: the placebo contrast is consistent, but “regardless” generalizes beyond the finite mapped definitions tested
   - Location: Key Summary Points; Conclusions

## Strengths

- **Convergent supportive analyses test robustness** The TEQ-only TOSR analysis and the VAS ceiling and floor TTCR analyses produced directionally consistent estimates, testing sensitivity to key mapping choices.
  - Dimension: methodological rigour
  - Location: Methods, Subgroup and Supportive Analyses; Results, Table 4
- **Clear bridge between trial eras** The Introduction identifies concrete differences between legacy VAS/TEQ studies and contemporary PGI-S/PGI-C trials, including severity eligibility, treatment timing, and home administration.
  - Dimension: contribution
  - Location: Introduction, paragraphs 3–6
- **Limitations linked to interpretation** The Discussion explains how severe-only enrollment, clinic treatment, interval censoring, missing assessments, and mapped PROs affect precision and generalizability rather than merely listing them.
  - Dimension: positioning
  - Location: Discussion, paragraphs 3–7

## Limitations

- **Contemporary outcomes were not directly measured** PGI-S and PGI-C were never collected in the source trials; the principal endpoints depend on mappings from legacy VAS and TEQ instruments.
  - Dimension: methodological rigour
  - Location: Methods, Assessments; Discussion, final paragraph
- **Censoring descriptions are not fully consistent** Statistical Analysis assigns fixed-window censoring to patients lacking post-baseline assessments, whereas the Discussion also describes censoring at the last evaluable assessment. This limits confidence in exact event-time estimates.
  - Dimension: methodological rigour
  - Location: Methods, Statistical Analysis; Discussion, paragraph on interval censoring and missing assessments
- **Population restricts contemporary transferability** All analyzed attacks were severe or very severe, approximately 95% of participants were White, and treatment occurred after clinic evaluation. These conditions differ from broader, earlier home treatment in contemporary care.
  - Dimension: application pathway
  - Location: Results, Table 1; Discussion, paragraphs 3–6

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The main sample sizes and efficacy estimates reconcile across the abstract, results, and tables. Exact time-to-event interpretation is qualified by inconsistent descriptions of censoring and a terminology slip that calls a 4.50-hour median a hazard ratio.
- **Research conduct:** Clean. The analysis identifies the registrations for the source trials and declares that no new human-participant study was conducted, so additional ethics approval was not required. No supplied-text conduct issue met the threshold for elevation.
- **Reference integrity:** Clean. 21 of 21 checkable references verified
  - 30 references in manuscript
  - 9 have no canonical index record — counted, but not index-checkable
  - 1 reference confirmed by manual review
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17